Research analysts at SunTrust Banks initiated coverage on shares of Urovant Sciences (NASDAQ:UROV) in a research report issued to clients and investors on Friday, The Fly reports. The firm set a “buy” rating on the stock.

Other equities research analysts have also issued reports about the company. Zacks Investment Research raised Urovant Sciences from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Tuesday, December 25th. HC Wainwright started coverage on Urovant Sciences in a report on Monday. They issued a “buy” rating and a $28.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Urovant Sciences has an average rating of “Buy” and a consensus price target of $19.55.

Shares of NASDAQ UROV opened at $13.75 on Friday. Urovant Sciences has a 1 year low of $4.05 and a 1 year high of $14.32.

Urovant Sciences (NASDAQ:UROV) last released its quarterly earnings data on Wednesday, February 13th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.22. Research analysts predict that Urovant Sciences will post -4.21 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Barclays PLC purchased a new stake in shares of Urovant Sciences during the fourth quarter worth $37,000. Two Sigma Investments LP purchased a new stake in shares of Urovant Sciences during the fourth quarter worth $72,000. Weiss Multi Strategy Advisers LLC raised its holdings in Urovant Sciences by 38.2% during the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock valued at $99,000 after buying an additional 4,146 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in Urovant Sciences during the third quarter valued at about $147,000. Finally, Man Group plc bought a new position in Urovant Sciences during the third quarter valued at about $300,000. Institutional investors and hedge funds own 22.77% of the company’s stock.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Recommended Story: Trading Strategy

The Fly

Analyst Recommendations for Urovant Sciences (NASDAQ:UROV)

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.